Metavia Inc. · NASDAQ:MTVA
Metavia — NeuroBo Pharmaceuticals — Investor Presentation (July 2024)
31 slides from Metavia's investor presentation, Jul 16, 2024
Slide 1: NeuroBo Pharmaceuticals, Inc.
December 2023 NASDAQ: NRBO 1 July 2024 NeuroBo Pharmaceuticals, Inc.
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the us
Slide 3: Strong Leadership Team
3 Strong Leadership Team Executive Management Hyung Heon Kim, Chief Executive Officer Robert Homolka, SVP Clinical Operations Marshall H. Woodworth, Chief Financial Officer Mi-Kyung Kim, Ph.D., RPh, Chief Scientific Officer ▪ 20+ years of experience in M&A, financing and corporate governance ▪ 10+ y
Slide 4: Compelling Investment Opportunity Targeting Obesity and MASH
4 Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics ▪ Aiming to increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1726 ✓ Ongoing Phase 1 trial for the treatment of obesity o Part 1 (SAD) data readout expe
Slide 5: Pipeline
5 Pipeline Asset Preclinical Phase 1 Phase 2 DA-1241 (GPR119 Agonist) DA-1726 (GLP1R/GCGR Dual Agonist) 2a 2b OBESITY Indication MASH Obesity
Slide 6: Multiple Near-Term Milestones: Targeting to Increase Shareholder Value
6 Multiple Near-Term Milestones: Targeting to Increase Shareholder Value Investments in the current DA-1241 Phase 2a and DA-1726 Phase 1 have the potential for significant returns in the event of clinical and regulatory success Q1/Q2 2025 Meeting with FDA 2024 2025 DA-1241 Q3 2024 Phase 2a Last Pati
Slide 7: DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline
7 DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline Phase 1 Part 3 will assess total weight loss at 24 weeks, exploring maximum titratable dose and dietary changes 2025 2026 DA-1726 Part 3 H1 2026 Part 3 Last Patient Visit Q3 2025 Part 3 First Patient Dosed H2 2026 Part 3 Top Line Results *
Slide 8: DA-1726: Upcoming Phase 1 Part 3 to Evaluate Early Proof of Concept and Maximum Titratable Dose
8 DA-1726: Upcoming Phase 1 Part 3 to Evaluate Early Proof of Concept and Maximum Titratable Dose Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, Phase 1 clinical trial to evaluate the efficacy and safety of DA-1726 in obese, otherwise healthy subjects Addi
Slide 9: DA-1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity
December 2023 NASDAQ: NRBO 9 DA -1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity
Slide 10: DA-1726: Indication - Obesity - Competitive Differentiation
10 DA-1726: Indication - Obesity - Competitive Differentiation Pemvidutide DA-1726 Mazdutide Survodutide Semaglutide Tirzepatide Developer Altimmune NeuroBo Innovent Biologics Lilly Boehringer Ingelheim Novo Nordisk Lilly Status Phase 3 ready Phase 1 Phase 3 (China, 9mg) Phase 2 (USA) NDA in China f
Slide 11: DA-1726: Potentially Best in Class Based on Key Attributes From Non-Clinical Studies
11 DA-1726: Potentially Best in Class Based on Key Attributes From Non-Clinical Studies Attribute DA-1726 Survodutide Semaglutide Tirzepatide Change in Body Weight Similar or Better Than Competition DA-1726 ~7% More Body Weight Loss while Consuming More Calories 2024 84th ADA Poster 2058-LB DA-1726
Slide 12: DA-1726: Mechanism of Action
12 DA-1726: Mechanism of Action DA-1726 is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/Glucagon Receptor); GLP-1 (Glucagon-Like Peptide 1) 1. Pocai A. Mol Metab.2014;3:241-51 ▪ Oxyntomodulin
Slide 13: DA-1726: Therapeutic Potential in Obesity — Semaglutide Comparison
13 DA-1726: Therapeutic Potential in Obesity(1-3) — Semaglutide Comparison DA-1726 outperformed Semaglutide (Wegovy®), a GLP-1 agonist, in mouse models of obesity* *Statistically significant compared to control Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); HF-DIO (High Fat
Slide 14: DA-1726: Therapeutic Potential in Obesity — Tirzepatide Comparison
14 DA-1726: Therapeutic Potential in Obesity (1,2) — Tirzepatide Comparison DA-1726 shows similar weight loss while consuming more food compared to Tirzepatide (Mounjaro®) Notes: HF-DIO (High Fat-Diet Induced Obesity); BWL (Body Weight Loss) 1. Dong-A Study Report 105497. All treatments given as twi
Slide 15: DA-1726: Comparative Study with Tirzepatide on Lipid-Lowering
15 DA-1726: Comparative Study with Tirzepatide on Lipid-Lowering Food Intake Lipid Profiles Liver Cholesterol DA-1726 was more effective in regulating lipid metabolism and suppressing weight gain, even though the hyperlipidemic rats had a similar food intake to those taking Tirzepatide Mean SEM, *
Slide 16: DA-1726: Comparative Study with Survodutide on Weight Loss & Lipid-Lowering
16 DA-1726: Comparative Study with Survodutide on Weight Loss & Lipid-Lowering Food Intake Plasma Biochemistry Analysis Body Weight Loss Notes: HF-DIO (High Fat-Diet Induced Obesity), EE (energy expenditure), BAT (brown adipose tissue) 1. Tae-Hyoung Kim et al. 84th Meeting of the American Diabetes A
Slide 17: DA-1726: Comparative Study with Survodutide on Fat Mass Loss
17 DA-1726: Comparative Study with Survodutide on Fat Mass Loss • DA-1726 demonstrated superior weight loss efficacy compared to Survodutide in HF-DIO mice under similar dietary intake conditions • DA-1726 demonstrated superior body fat mass reduction and lean body mass relative preservation compare
Slide 18: DA-1726: Phase 1 Part 1 & 2 to Evaluate Safety and Tolerability
18 DA-1726: Phase 1 Part 1 & 2 to Evaluate Safety and Tolerability Rationale for study ▪ Gain a robust understanding of safety, tolerability of various dose levels in humans ▪ Superior weight loss compared with the pair-fed group, indicating much of the weight loss was attributed to reduced food int
Slide 19: DA-1726: Upcoming Phase 1 Part 3 to Evaluate Early Proof of Concept and Maximum Titratable Dose
19 DA-1726: Upcoming Phase 1 Part 3 to Evaluate Early Proof of Concept and Maximum Titratable Dose Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, Phase 1 clinical trial to evaluate the efficacy and safety of DA-1726 in obese, otherwise healthy subjects Add
Slide 20: DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH
December 2023 NASDAQ: NRBO 20 DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH
Slide 21: DA-1241: Competitive Differentiation
21 DA-1241: Competitive Differentiation 1. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3 Resmetirom DA-1241 Developer Madrigal NeuroBo Indication MASH MASH Status Approved Phase 2 Action THR (Thyroid hormone receptor) β a
Slide 22: DA-1241 Effect on Pathogenesis in MASH as a Monotherapy
22 DA-1241 Effect on Pathogenesis in MASH as a Monotherapy GPR119 activation: Monocytes and macrophages ▪ Macrophage activation ▪ Monocyte recruitment ▪ Macrophage differentiation → Reduction in hepatic and systemic inflammation Hepatic stellate cells Stellate cell activation → Reduce hepatic fibrog
Slide 23: GPR119 in MASH Pathogenesis when Co-Administered with Other Therapies
23 GPR119 in MASH Pathogenesis when Co-Administered with Other Therapies ▪ Effectively decreased hepatic inflammation ▪ Reduced systemic inflammation and fibrosis biomarkers ▪ Reduced hepatic lipid and collagen deposition in the liver of MASH mice Activation of GLP1 Receptor Effects ▪ Pancreas • Inc
Slide 24: DA-1241: Ongoing Phase 2a in MASH
24 DA-1241: Ongoing Phase 2a in MASH Support use as a monotherapy Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepatitis Primar
Slide 25: Financials and Capitalization
December 2023 NASDAQ: NRBO 25 Financials and Capitalization
Slide 26: Cash Balance and Capitalization Table
26 Cash Balance and Capitalization Table Projected Cash Balance As of March 31, 2024 Cash(1) $16.0 million Debt None Projected Capitalization Table as of March 31, 2024 Common Stock Equivalents Common Stock(1) 4,906,002 Warrants (WAEP $145.54)(1)(2)(3) 203,914 Options (WAEP $398.30) 4,700 Restricted
Slide 27: Multiple Near-Term Milestones: Targeting to Increase Shareholder Value
27 Multiple Near-Term Milestones: Targeting to Increase Shareholder Value Investments in the current DA-1241 Phase 2a and DA-1726 Phase 1 have the potential for significant returns in the event of clinical and regulatory success Q1/Q2 2025 Meeting with FDA 2024 2025 DA-1241 Q3 2024 Phase 2a Last Pat
Slide 28: DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline
28 DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline Phase 1 Part 3 will assess total weight loss at 24 weeks, exploring maximum titratable dose and dietary changes. 2025 2026 DA-1726 Part 3 H1 2026 Part 3 Last Patient Visit Q3 2025 Part 3 First Patient Dosed H2 2026 Part 3 Top Line Results
Slide 29: Investment Thesis
December 2023 NASDAQ: NRBO 29 Investment Thesis
Slide 30: Compelling Investment Opportunity Targeting Obesity and MASH
30 Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics ▪ Aiming to increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1726 ✓ Ongoing Phase 1 trial for the treatment of obesity o Part 1 (SAD) data readout exp
Slide 31: Thank You! Investor Contacts
December 2023 NASDAQ: NRBO 31 Thank You! Investor Contacts: Rx Communications Group Michael Miller +1 917.633.6086 mmiller@rxir.com NeuroBo Pharmaceuticals Marshall Woodworth +1 919.749.8748 marshall.woodworth@neurobopharma.com
NeuroBo Pharmaceuticals — Investor Presentation (July 2024) on 6ix